Viking Therapeutics Strong Analyst Confidence – Price Target Well Above Current Price
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics (VKTX) closed at $33.30 on July 7, 2026, a decline of 1.33% from the previous day.
- 23 of 24 analysts recommend the stock for purchase (22 Buy, 1 Strong Buy), with no analyst recommending a sell (as of July 7, 2026).
- The average price target is $93.60, with a range from $83.00 to $101.00 – an upside potential of roughly 181%.
- The RSI stood at 68.02 points on July 6, 2026, after rising above 70 multiple times in late June.
- VK2809, the leading pipeline candidate, is undergoing Phase IIb trials for the treatment of NASH and NAFLD.
Viking Therapeutics Inc. (VKTX) closed at $33.30 on July 7, 2026, marking a decline of 1.33 percent from the previous day ($33.75). The biotech company focused on metabolic and endocrine disorders is at the center of positive analyst ratings that signal substantial upside potential.
Broad Analyst Consensus Supports Positive Assessment
Of a total of 24 analysts covering Viking Therapeutics, 22 recommend the stock for purchase, while one analyst issues a Strong Buy recommendation (as of July 7, 2026). Only one analyst advises holding the position – sell recommendations are completely absent. This distribution underscores high confidence in the company's prospects.
The average analyst price target is $93.60, with a median of $95.00. The range extends from a conservative target of $83.00 to an optimistic scenario of $101.00. Based on the current price, this yields a calculated upside potential of approximately 181 percent to the mean.
Technical Indicators Point to Consolidation
The Relative Strength Index (RSI) stood at 68.02 points on July 6, 2026. An RSI above 70 is typically considered overbought, while a value below 30 is considered oversold. Viking Therapeutics is trading in the upper neutral range, after the RSI rose above the 70-point mark multiple times in late June – reaching 75.03 on June 24 and 75.36 on June 29.
Trading volume on July 7, 2026 was just 2,997 shares – a significantly below-average figure indicating low market activity. The day's range was between $33.30 (low) and $33.75 (high).
Pipeline with Advanced Development Candidates
Viking Therapeutics operates several development programs as a clinical biotech company. The leading candidate VK2809 is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRβ). The molecule is undergoing Phase IIb trials for the treatment of non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients as well as non-alcoholic fatty liver disease (NAFLD).
Additional compounds in the pipeline include VK5211, an oral, non-steroidal selective androgen receptor modulator in Phase II trials for patients following hip fracture surgery, as well as VK0612, an oral candidate for type 2 diabetes that is approaching Phase IIb trials.
Market Position in Competitive Segment
The company operates in the highly competitive field of metabolic disorders, where several major pharmaceutical companies and specialized biotechs are active. The treatment of NASH and NAFLD is considered a medical need with high commercial potential, as effective therapies are currently lacking. Market development depends largely on clinical trial results and regulatory approvals.
Viking Therapeutics has gone through a phase of technical strength in recent weeks, reflected in the RSI values. The current consolidation around $33 could represent a pause following previous gains. Investors are closely monitoring progress in ongoing clinical programs, as these determine the company's long-term value.